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Summary
T helper type 17 (Th17) cells play a pathogenic role in autoimmune disease,
while interleukin (IL)-10-producing Th10 cells serve a protective role. The
balance between the two subsets is regulated by the local cytokine milieu and
by the relative expression of intact forkhead box protein 3 (FoxP3) compared
to FoxP3Δ2, missing exon 2. Th17 and Th10 cell differentiation has usually
been studied using polyclonal stimuli, and little is known about the ability of
physiologically relevant self-antigens to induce Th17 or Th10 cell differentia-
tion in autoimmune thyroid disease. We subjected mononuclear cells from
healthy donors and patients with Hashimoto’s thyroiditis (HT) or Graves’
disease (GD) to polyclonal stimulation, or stimulation with human
thyroglobulin (TG), human thyroid peroxidase (TPO), or Esherichia coli
lipopolysaccharide (LPS). TPO and LPS induced increased differentiation of
naive CD4+CD45RA+CD45R0– T cells from HT patients into Th17 cells. Th10
cell proportions were decreased in HT after polyclonal stimulation, but were
comparable to those of healthy donors after antigen-specific stimulation.
Taken together, our data show that an increased Th17 : Th10 ratio was found
in HT patients after stimulation with thyroid-specific self-antigens. We also
observed an elevated baseline production of IL-6 and transforming growth
factor (TGF)-β1 and of mRNA encoding FoxP3Δ2 rather than intact FoxP3.
This may contribute to the skewing towards Th17 cell responses in HT.
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Introduction
Autoimmune thyroid disease (AITD) includes Hashimoto’s
thyroiditis (HT) and Graves’ disease (GD), which are
characterized by the breakdown of immune self-tolerance
towards thyroid antigens followed by lymphocytic infiltra-
tion of the thyroid gland (reviewed in Weetman [1]). In
HT, T cells cause the destruction of thyroid epithelial
architecture leading to hypothyroidism. In contrast, GD is
characterized by generation of autoantibodies against the
thyroid stimulating hormone receptor (TSHR). These
stimulate thyrocytes and promote thyroid hormone over-
production and result in hyperthyroidism [1]. Immune
responses against two major thyroid self-antigens,
thyroglobulin (TG) and thyroid peroxidase (TPO), are
frequently associated with both HT and GD, as is
evidenced by the high prevalence of anti-TG and anti-TPO
antibodies [1].
CD4+ T cells play essential roles in adaptive immune
responses by virtue of their production of cytokines.
Mosmann and colleagues demonstrated that CD4+ T helper
(Th) cells can be subdivided into Th1 and Th2 cells on the
basis of distinct cytokine profiles [2–4]. Signature Th1
cytokines include interferon (IFN)-γ, while interleukin-4
(IL-4) production represents the Th2 prototype [2–4]. Sub-
stantial evidence links Th1 cells to the pathogenesis of
AITD [5–9]. Relatively recent insights have revealed a third
Th cell subset that generates IL-17 [10]. These, designated
Th17 cells, play important roles in the clearance of
extracellular pathogens [11]. Th17 cells have been associ-
ated with several autoimmune diseases, including rheuma-
toid arthritis, psoriasis, inflammatory bowel disease,
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neuromyelitis optica and multiple sclerosis [11–13]. Recent
studies have demonstrated increased proportions of Th17
cells in peripheral blood from patients with HT or GD fol-
lowing polyclonal stimulation [13–16].
Regulatory T cells (Tregs) represent a fourth CD4+ T cell
subset that is critical in maintaining tolerance to self-
antigens [17]. Tregs can be classified as either natural Tregs
(nTregs), which leave the thymus as mature cells [17,18], or
as inducible Tregs (iTregs), which are generated from naive
CD4+ T cells in the periphery after antigenic stimulation
[18] (reviewed in [19]). nTregs are identified as CD4+ T cells
expressing the transcription factor forkhead box protein 3
(FoxP3) and expressing high levels of the IL-2 receptor
α-chain, CD25 [20–22]. iTregs are distinguished by their pro-
duction of IL-10 or transforming growth factor (TGF)-β
[18,19]. However, iTregs may also acquire expression of
FoxP3/CD25 [23], while nTregs may produce IL-10/TGF-β
[24–26], making the two subsets difficult to distinguish. In a
few studies, the term ‘Th10’ cells has been applied to IL-10-
producing CD4+ T cells, irrespective of their origins [27].
Grouping HT and GD together as AITD, Glick et al. found
equal numbers of CD25hi FoxP3+ Tregs circulating in indi-
viduals with AITD and healthy controls [28]. Pan et al.
reported similar findings in GD [29]. Previously, we dem-
onstrated that the thyroid self-antigens, TG and TPO, could
induce IL-10 production in human mononuclear cells
(MNCs) [30–32].
A high degree of ‘plasticity’ exists between Th17 cells and
iTregs. Low concentrations of TGF-β in combination with
IL-6, IL-21 or IL-1β drive Th17 differentiation from naive
Th cells (Th0 cells) [11,33–36]. In the absence of the afore-
mentioned proinflammatory cytokines, TGF-β drives iTreg
differentiation [11,37]. Also, CD25hiFoxP3+ Th cells within
the memory cell (CD45R0+) compartment [38] can be con-
verted into Th17 cells [39,40]. IL-23 may be important in
maintaining Th17 cells once fully differentiated [41], as well
as in acquisition of full Th17 pathology [42].
Studies on Tregs and Th17 have generally involved
polyclonal stimulation, typically with phorbol 12-myristate
13-acetate (PMA)/ionomycin [13–16]. Th17-cell differen-
tiation following more physiologically relevant stimulation,
such as with self-antigens, has yet to be examined. One
study used microbial pathogens as a stimulus and found,
surprisingly, that Candida albicans and Staphylococcus
aureus both prime Th17 cells with co-production of IFN-γ
and IL-10, respectively, depending on whether IL-1β or IL-2
was present [43]. Little is known about the ability of self-
antigens to induce IL-17 and IL-10 production by human
Th cells. We have demonstrated previously that TG induces
IL-10 production by CD4+ T helper cells with a CD45R0+
phenotype [31], and that other self-antigens, such as myelin
basic protein, induce IL-17 production in cultured periph-
eral blood mononuclear cells (PBMCs) from healthy con-
trols [44]. To our knowledge, no studies have addressed the
polarization of human CD4+ T cells into Th17 cells driven
by thyroid self-antigens, or examined the balance between
Th17 cells and Th10 cells in healthy individuals and those
with AITD.
Here we report that TG and TPO can induce IL-17 and
IL-10 in circulating CD4+ T cells from patients with AITD
and those from healthy donors. We also assessed the induc-
tion of IL-6-producing CD4+ T cells. Finally, we determined
whether the self-reactive Th17 and Th10 cells represent
reactivated memory cells or differentiate de novo from the
pool of circulating naive Th cells.
Materials and methods
Patients
The study included 10 patients with HT (defined as serum
TSH above 10 IU/l, and serum TPO antibodies > 100 U/l
and absence of TSHR antibodies) and 11 patients with GD
(defined as a suppressed serum TSH with increased serum
freeT4 (FT4) and freeT3 (FT3), elevated serum TSHR anti-
bodies, diffuse uptake on thyroid scintigraphy and ultra-
sound demonstrating diffuse hypoechogenicity), attending
the endocrinology out-patient clinic at Odense University
Hospital between August 2012 and October 2013. All
patients were diagnosed within 3 years of study participa-
tion, with the exception of one HT patient diagnosed in
2006. Clinical characteristics for the patients at the time
of blood collection are shown in Table 1. Eight HT
Table 1. Patient characteristics.
Graves’ disease Hashimoto’s thyroiditis
(n = 11) (n = 10)
Age (years)
Median 45·0 45·5
Interquartile range 27−77 24−74
Gender (% females) 72·7 90·0
Thyroid hormone levels
TSH (mIU/l)† 2·8 ± 6·4 4·7 ± 2·9**
T3 (nmol/l)‡ 2·6 ± 1·1 1·7 ± 0·5*
T4 (nmol/l)§ 117·9 ± 51·6 87·5 ± 26·2
T4 uptake (nmol/l)¶ 1·0 ± 0·2 1·0 ± 0·2
FT3†† 2·8 ± 1·5 1·6 ± 0·2**
FT4†† 122·8 ± 53·4 85·0 ± 13·1
Autoantibodies
Anti-TSHR (kIU/l)‡‡ 7·1 ± 8·5 Negative
Anti-TPO (kIU/l)§§ 327·9 ± 721·5 1379·7 ± 1092·5
All thyroid hormone and autoantibody levels are taken at the time
of immunological studies. †Normal range: 0·3–4·0 mIU/l; ‡normal
range: 1·3–2·2 nmol/l; §normal range: 60–130 nmol/l; ¶normal range:
0·6–1·2 nmol/l; ††FT3 or FT4 were defined as T3 or T4 divided by T4
uptake; ‡‡positive >1·0 kIU/l; §§normal range: 2·1–9·8 kIU/l. *P < 0·05;
**P < 0·01 between Hashimoto’s thyroiditis (HT) and Graves’ disease
(GD) patients. TSH = thyroid stimulating hormone; TSHR = thyroid
stimulating hormone receptor; TPO = thyroid peroxidase.
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patients were receiving levothyroxin [median = 75 μg/day,
interquartile range (IQR) = 50–100 μg/day], while nine GD
patients were receiving methimazole (median = 15 mg/day,
IQR = 5–20 mg/day) at the time of blood collection. The
duration of anti-thyroid treatment at the time of blood col-
lection varied from 2 weeks to 8 years. Fifteen anonymous
healthy donors with no history of autoimmune disease (11
females, four males, median age 46 years) attending the
Blood Bank at Copenhagen University Hospital served as
controls. The study was approved by the Ethical Committee
from the Region of Southern Denmark (project no. 28699)
and followed the guidelines outlined in the Declaration of
Helsinki. Written informed consent was obtained from all
included patients.
Biochemistry
Serum TSH was measured by solid-phase, two-site
chemiluminescent immunometric assay on an Immulite
2000 equipment (Siemens, Erlangen, Germany). The limit
of detection for TSH was 0·004 mIU/l. T4 and T3 were
measured using time-resolved fluoroimmunoassays based
on competitive binding to T3- or T4-specific antibodies,
respectively, on AutoDELFIA equipment (Perkin Elmer/
Wallac, Turku, Finland). The limit of detection was
0·3 mmol/l for T3 and 5·0 mmol/l for T4. FT3 and FT4
were defined as T3 or T4 divided by T4 uptake. Anti-TPO
antibodies were measured by solid-phase time-resolved
fluoroimmunometric assays (AutoDELFIA), and anti-
TSHR antibodies were measured by DynOtest TRAK
human radio receptor assay (Brahms Diagnostica, Berlin,
Germany). The limits of detection for anti-TPO antibodies
and anti-TSHR antibodies were <1·0 kIU/l and 0·3 U/l,
respectively.
Reference ranges were 0·3–4·0 mIU/l for TSH, 1·3–
2·2 nmol/l for T3, 60–130 nmol/l for T4, 0·6–1·2 nmol/l for
T4 uptake, 2·1–9·8 kIU/l for anti-TPO antibodies. Samples
were regarded as positive for anti-TSHR antibodies if above
1·0 kIU/l.
Cells and serum
Venous blood was collected in tubes with or without
heparin (BD Vacutainer Systems, Plymouth, UK). For isola-
tion of PBMCs, blood samples were centrifuged over
LymphoPrepTM (Axis-Shield, Oslo, Norway) at 1200 g,
without brake, for 30 min. The cells were washed twice in
phosphate-buffered saline (Gibco/Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) by spinning at 400 g for
10 min. All subsequent centrifugations were carried out at
400 g. Human serum isolated from healthy male donors of
blood group AB (AB serum) was purchased from Lonza
(Basel, Switzerland; cat. no. 14-490E) and used as the serum
source in all experiments.
Antibodies
Cells were stained using a combination of the following
antibodies: anti-CD4 peridinin chlorophyll (PerCP) (cat.
no. 345–770), anti-CD45RA fluorescein isothiocyanate
(FITC) (cat. no. 555-488), anti-CD45R0 allophycocyanin
(APC) (cat. no. 559–865), anti-IL-6 phycoerythin (PE) (cat.
no. 340–527), anti-IL-17A PE (cat. no. 560-436) or IL-10 PE
(cat. no. 559-330). All antibodies were purchased from BD
Biosciences (San Jose, CA, USA) and were used according to
the manufacturer’s instructions.
Antigens
Human TG (MW 660 kDa) purified from thyroid tissue was
purchased from Aviva Systems Biology (San Diego, CA,
USA; cat. no. OPSA10707) and was found to contain endo-
toxin using the Limulus amebocyte lysate assay (QCL-1000
chromogenic LAL; Lonza; cat. no. 50-647U). Endotoxin was
removed using Triton X-114 as described previously [45].
Human reconstituted TPO (MW 18·6 kDa) was a generous
gift from Marlena Godlewska (Medical Centre of Post-
graduate Education, Warsaw, Poland). Escherichia coli
lipopolysaccharide (LPS) O111:B4 strain (Sigma Aldrich, St
Louis, MO, USA; cat. no. L2630) was used as a foreign
control antigen.
PBMC cultures
PBMCs were inoculated onto flat-bottomed 96-well
Nunc Microtitre Nunclon plates (Fisher Scientific,
Loughborough, UK) at a density of 5 × 105 cells/well. These
were stimulated with TG (30 μg/ml), TPO (30 μg/ml) or E.
coli LPS (50 ng/ml) in RPMI-1640 medium containing
L-glutamine (Gibco/Invitrogen Life Technologies), gen-
tamicin (50 μg/ml; Lonza) and 30% (v/v) human AB serum
(Lonza) to a final volume of 100 μl per well. One well per
donor was stimulated with anti-CD3/anti-CD28 micro-
Dynabeads® (Life Technologies). Unstimulated cells (no
antigen) served as negative controls. Cultures were incu-
bated in a humidified 5% CO2 incubator at 37°C for 18
or 48 h.
Cytokine measurements
For IL-17A and IL-6, brefeldin A (cat. no. 420601;
Biolegend, San Diego, CA, USA) was added (1 μl/well) to
PBMCs after the initial 6 h of antigen stimulation. After a
further 12 h incubation, cells were stained with anti-CD4
PerCP, anti-CD45RA FITC and anti-CD45R0 APC. For
intracellular staining, cells were fixed and made permeable
using CytoFix/CytoPerm (cat. no. 554–722; BD Biosciences,
San Jose, CA, USA) and stained with anti-IL-17A PE or
anti-IL-6 PE. For IL-10 staining, cultures were incubated for
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48 h and brefeldin A was added during the final 6 h. Culture
supernatants were collected after 18 h and assessed for levels
of IL-1β, IL-6 and TGF-β1 by Luminex (Austin, TX, USA).
Multiplex beads were supplied by Bio-Rad (Hercules, CA,
USA).
Flow cytometry
After stimulation, cells were washed and resuspended in
phosphate-buffered saline and stained. A FACS Canto (BD
Biosciences) flow cytometer with argon laser (488 nm) and
helium–neon laser (633 nm) excitation was used to acquire
fluorescence, and the FACS Diva software (BD Biosciences)
was used for analysis.
RNA purification and cDNA synthesis
Following stimulation with TG, TPO or E. coli LPS, mRNA
was extracted, purified, and isolated using Qiashredder (cat.
no. 79654; Qiagen, Hilden, Germany) and RNeasy Mini
Kit (cat. no. 74104; Qiagen). cDNA was synthesized as
described previously [46]. The reaction conditions were as
follows: 42°C for 30 min, 99°C for 5 min and 4°C for
10 min [47].
Quantitiative reverse transcription–polymerase chain
reaction (qRT–PCR)
qRT–PCR was used for quantification of mRNA encoding
FoxP3 (referred to as total FoxP3, comprising all isoforms)
or the FoxP3Δ2 isoform, specifically as described [46]. CD4
served as the house-keeping gene, as its expression is invari-
ant with respect to stimulation [48]. The cycle threshold
(Ct) values were averaged and normalized against the corre-
sponding CD4 values (ΔCt).
Statistics
Comparisons between each patient group and healthy con-
trols were conducted using the two-tailed Mann–Whitney
U-test. Differences between HT and GD patients were con-
sidered subordinate. Correlation between cytokine produc-
tion and thyroid hormones, TSH or TSHR-antibody levels
was evaluated using Spearman’s rank correlation coeffi-
cient. All analysis was carried out using GraphPad Prism
version 6·00 (GraphPad Software, La Jolla, CA, USA). Raw
P-values are presented in the figures, and Bonferroni-
adjusted P-values (raw P-values multiplied by 2) are given
in the text body. Adjusted P-values < 0·05 were considered
significant.
Results
Induction of IL-17-, IL-10- and IL-6-producing Th cells
by anti-CD3/anti-CD28 stimulation
PBMCs from 15 healthy controls, 11 patients with GD and
10 with HT were isolated and stimulated with anti-CD3/
anti-CD28 micro-Dynabeads®. The frequencies of Th cells
producing IL-17, IL-10 or IL-6 were examined by flow
cytometry, following the gating strategy shown in Fig. 1a,b.
The frequency of Th cells was similar in all three donor
groups as determined by flow cytometry (data not shown).
The stimulation provoked differentiation of 5 per 10 000
Th cells in HT patients, 0·4 per 10 000 Th cells in GD
patients and 10 per 10 000 Th cells into Th17 cells in cul-
tures derived from healthy controls (Fig. 1c). Neither of the
patient groups deviated significantly from the healthy con-
trols. A positive correlation was observed in HT patients
between circulating TSH levels and the proportion of com-
mitted Th17 cells, as determined by the proportion of Th17
cells induced by anti-CD3/anti-CD28 beads (Rs = 0·78,
P = 0·048; data not shown).
A smaller proportion of Th10 cells was induced in cul-
tures from HT patients (10 per 10 000 Th cells) than in cul-
tures from healthy donors (44 per 10 000 Th cells, adjusted
P-value = 0·028), as shown in Fig. 1d. The proportion in
GD was intermediate (24 per 10 000 Th cells). No signifi-
cant associations were observed between FT3 or FT4 and
Th10 differentiation.
Polyclonal activation failed to yield IL-6 producing Th
cells in any donor group (Fig. 1e).
Induction of Th17 cells by thyroid self-antigens and
E. coli LPS
We next examined the induction of cytokine-producing Th
cells by the thyroid self-antigens TG and TPO (Fig. 2).
E. coli LPS, which is known to expand pre-existing Th17
cells, was used as a foreign control antigen [49]. To distin-
guish between naive and memory Th cells, PBMC cultures
were co-stained with anti-CD45RA and anti-CD45R0 anti-
bodies (Fig. 2a). Before cultivation, similar ratios of naive
and memory Th cells were found in the three donor groups
(GD: 33 versus 29%; HT: 29 versus 34%; and healthy con-
trols: 33 versus 29%, respectively) (data not shown).
TG induced IL-17 production in 8·4 per 10 000 naive Th
cells from HT patients, 4·8 per 10 000 naive Th cells from
GD patients and 2·8 per 10 000 naive Th cells from healthy
donors (Fig. 2b,c). The corresponding proportions in the
memory cell compartment were 4·0 per 10 000 Th cells
from HT patients, 2·1 per 10 000 Th cells from GD patients
and 5·3 per 10 000 Th cells from healthy donors (Fig. 2d).
These proportions did not differ significantly between the
groups.
TPO induced IL-17 production in 2·8 per 10 000 naive
Th cells from individuals with HT, but in no cells from GD
patients or healthy donors (adjusted P = 0·016 versus HT
patients), as shown in Fig. 2c. In the memory cell compart-
ment, TPO failed to induce IL-17 production in all three
groups (Fig. 2d).
E. coli LPS stimulated IL-17 production in naive Th cells
from HT (11·9 per 10 000 cells) but failed to do so in this
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compartment from GD patients or healthy donors
(adjusted P = 0·014, HT versus healthy donors), as shown in
Fig. 2c. The proportion of memory Th cells induced by
E. coli LPS was greater in HT (19·2 per 10 000 cells) than in
healthy controls (1·4 per 10 000 cells; adjusted P = 0·027;
Fig. 2d).
Induction of Th10 cells by thyroid self-antigens and
E. coli LPS
To examine induction of Th10 cells, PBMCs were stimu-
lated with TG, TPO or E. coli LPS for 48 h.
TG induced IL-10 production in 2·6 per 10 000 naive Th
cells from HT patients, no naive Th cells from GD patients
and 1·9 naive Th cells from healthy controls (Fig. 3a).
Moreover, IL-10 production was induced by TG in 5·5 per
10 000 memory Th cells from HT patients, 1·2 per 10 000
memory Th cells from GD patients and 2·6 per 10 000
memory Th cells from healthy donors. None of these
responses were significantly different in the three donor
groups.
TPO and E. coli LPS induced Th10 cells uniformly in the
three donor groups. The medians ranged from 0 to 3·5-
induced Th10 cells per 10 000 Th cells in both the naive and
memory cell compartments (Fig. 3a,b). Notably, a negative
association was observed between circulating anti-TSHR
antibody levels in GD patients and the proportion of TPO-
induced Th10 cells in the naive Th compartment (Fig. 3c).
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Fig. 1. Quantification of T helper (Th)17-, Th10- and interleukin (IL)-6-producing Th cells in subjects with autoimmune thyroid disease (AITD)
and healthy controls. Peripheral blood mononuclear cell (PBMC) cultures were stimulated with anti-CD3/anti-CD28 micro-Dynabeads and stained
for intracellular cytokine content. (a) Within a morphological lymphocyte gate (left panel) CD4+ Th cells were gated (right panel). (b) Cytokine-
producing cells were defined as positive when appearing within the gate shown. The left panel shows the background (unstimulated CD4+ Th cells),
while the right panel demonstrates CD4+ Th cells stimulated with anti-CD3/anti-CD28. (c) The proportion of Th17 cells, (d) Th10 cells and (e)
IL-6-producing Th cells are shown for eight healthy controls (HC), seven patients with Graves’ disease (GD) and seven patients with Hashimoto’s
thyroiditis (HT). The respective proportions observed in the absence of a stimulating antigen have been subtracted. Box-plots indicate median,
interquartile range (box) and range (whiskers). Raw P-values are shown (Mann–Whitney U-test); negative net values were included in calculations.
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Relationship between antigen-induced Th17 and
Th10 cells
Naive Th cells from HT donors differentiated preferentially
into Th17 cells after stimulation with TG, TPO or E. coli
LPS. The Th17 : Th10 ratio was 6·73 after stimulation with
TG, 4·43 after stimulation with TPO and 3·73 after stimula-
tion with E. coli (Fig. 4a). The corresponding ratios in
donors with GD were 1·63, 1·54 and 0·26, respectively. By
contrast, naive Th cells from healthy controls differentiated
preferentially towards the Th10 phenotype rather than
Th17. After stimulation with TG, the Th17 : Th10 ratio was
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Fig. 2. T helper (Th)17 cell differentiation driven by thyroid self-antigens. Peripheral blood mononuclear cells (PBMCs) were incubated with
thyroglobulin (TG), thyroid peroxidase (TPO) or Escherichia coli lipopolysaccharide (LPS) for 18 h, and CD4+interleukin (IL)-17+ Th cells were
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(P2), respectively. (b) Th17+ cells were identified as events within the P3 gate. Left panel shows naive unstimulated CD4+ Th cells (no antigen); right
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of naive Th17+ cells in PBMC cultures derived from healthy controls (HC, n = 15), donors with Graves’ disease (n = 11) and donors with
Hashimoto’s thyroiditis (n = 10). (d) Corresponding proportions of memory Th17+ cells are shown. Proportions observed in the absence of
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n = 11) and patients with Hashimoto’s thyroiditis (HT, n = 10). (b) Corresponding proportions of memory Th10+ cells are shown. Corresponding
proportions observed in the absence of antigen have been subtracted. (c) The proportion of naive Th10+ cells in GD patients (n = 11) after TPO
stimulation is shown against circulating levels of anti- thyroid stimulating hormone receptor (TSHR) antibodies (kIU/l). Spearman’s rank
correlation coefficient (Rs) and level of significance are shown; negative net values were included in calculations. Box-plots indicate median,
interquartile range (box) and range (whiskers).
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0·46 (adjusted P = 0·017 versus HT patients and P = 0·044
versus GD patients). Positive Th17 : Th10 ratios were found
in healthy donors after stimulation with TPO or E. coli LPS
(1·64 and 1·50, respectively).
Similar tendencies were found in the memory Th cell
population, although statistical significance was not reached
(Fig. 4b).
Th17-related cytokines in culture supernatants
To examine whether the local cytokine milieu determined
the propensity of naive Th cells to differentiate to Th17 cells
(Figs 2c and 4), TGF-β1, IL-6 and IL-1β concentrations
were assessed in conditioned medium from antigen-
stimulated cell cultures.
The TGF-β1 levels were significantly higher in cultures
from HT and GD patients than in those from healthy
donors, regardless of antigenic stimulus (adjusted
P = 0·0004–0·04; Fig. 5a). Stimulation with TG, TPO or E.
coli LPS failed to enhance TGF-β1 levels in any group.
Although variable, baseline IL-6 production was higher
in cultures from HT patients than those from healthy
donors (adjusted P = 0·038; Fig. 5b), while cultures from
GD patients had baseline levels similar to those of healthy
donors. Only in cultures from healthy donors did incuba-
tion with TG or TPO induce IL-6 above the basal level
(P = 0·019 and P = 0·0002, respectively). E. coli LPS induced
IL-6 in all donor groups above the basal levels (P < 0·0001–
0·0022), with no differences between groups.
The baseline production of IL-1β did not differ between
the donor groups (Fig. 5c). Only in the control group did
TG and TPO induce IL-1β production (P = 0·032 and
P = 0·015, respectively). TG-induced IL-1β in the GD group
was lower than that in healthy donors (adjusted P = 0·0098;
Fig. 5c), while the TPO-induced IL-1β production tended
to be lower among HT patients than among healthy donors
(P = 0·060). As anticipated, a dramatic increase in IL-1β
production was observed following stimulation with E. coli
LPS in all donor groups (P < 0·0001–0·0022), but neither of
the patient groups differed from healthy donors in this
respect (Fig. 5c).
Measurement of total FoxP3 and the splice
variant FoxP3Δ2
The induction of total FoxP3 mRNA and mRNA encoding
the splice variant FoxP3Δ2 was examined after stimulation
with anti-CD3/anti-CD28 beads (Fig. 6a,b), as well as after
antigen-specific stimulation (Fig. 6c,d). While the baseline
expression of total FoxP3 mRNA was similar in the three
donor groups (Fig. 6a,c), both patient groups displayed
higher constitutive expression of FoxP3Δ2 than did healthy
donors (adjusted P = 0·012 in both cases; Fig. 6b,d).
While stimulation with TG or TPO had no significant
effect on the total FoxP3 expression or on the expression of
FoxP3Δ2 among cells from HT patients, both self-antigens
significantly increased FoxP3Δ2 expression among GD
patients (P = 0·029 in both cases; Fig. 6c,d). Moreover,
stimulation with TPO significantly increased the expression
of total FoxP3 (P = 0·014) as well as of FoxP3Δ2 (P = 0·011)
in healthy donors. Stimulation with E. coli LPS failed to
increase the expression of total FoxP3 or FoxP3Δ2 in HT
patients, but robustly increased the expression of both total
FoxP3 and FoxP3Δ2 in cells from GD patients (P = 0·029 in
both cases) and healthy donors (P = 0·0003 in both cases;
Fig. 6c,d).
Regardless of whether stimulated or not, FoxP3Δ2 consti-
tuted approximately 30% of the total FoxP3 expressed in
cells from healthy donors, compared to 59–67% for HT
patients and 65–73% for GD patients (P = 0·008 for all
comparisons; Fig. 6e,f).
Discussion
Th17 cells are thought to play a pathogenic role in organ-
specific autoimmune diseases [11]. In contrast, Tregs, includ-
ing Th10 cells, exert immunoregulatory actions and in so
doing protect against autoimmune disease manifestations
[28,29]. The induction of Th17 and Th10 cells by disease-
relevant self-antigens has not been characterized previously
in AITD, nor has the balance between them. It is well
known that Th0 cells can differentiate into Th17 cells or
IL-10 producing iTregs under the influence of TGF-β in
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concert with other cytokines [11,33–36]. Conversely,
FoxP3+CD25hi Tregs displaying CD45RA−CD45R0+ can also
take on the Th17 phenotype [38]. We therefore investigated
whether TG or TPO could drive Th17 and Th10 responses
by naive and memory Th cells. It should be noted that the
term Th10 cells, used in this report, may comprise iTregs/Tr1
cells [18] as well as IL-10 producing nTregs [17,23,26] and
even a subset of Th17 cells [40] which may also produce
IL-10. Our staining protocol did not allow distinction
between these subsets. The possibility exists that a propor-
tion of Th17/Th10 cells reported here produce both
cytokines.
Studies of Th17 cells often employ phorbol myristate
acetate (PMA)/ionomycin or anti-CD3/anti-CD28-coated
beads to induce IL-17 production. Using this strategy,
earlier studies have detected an increased abundance of
circulating Th17 cells in individuals with HT or GD com-
pared to healthy donors [13–16]. Our findings are congru-
ent with these findings, but failed to reach statistical
significance. However, within the HT group, we identified a
positive correlation between TSH levels and anti-CD3/anti-
CD28-induced Th17 cells. Importantly, fewer Th10 cells
were induced by anti-CD3/anti-CD28 in HT-derived cell
cultures than in those derived from healthy donors, sug-
gesting that impairment of Th10 responses could also be
associated with HT. Induction of Th17 cells by disease-
relevant thyroid self-antigens has, to our knowledge, not
been studied before.
A modest differentiation of naive Th cells into Th17 cells
was observed in all three donor groups following stimula-
tion with TG. In contrast, TPO induced Th17 cells only in
cultures derived from HT patients, and only in the naive Th
cell compartment. The increase of Th17 cells in cultures
from HT patients was also observed in LPS-stimulated
naive and memory Th cells. Thus, the increased propensity
of Th cells from HT patients to differentiate into Th17 cells
following stimulation is not restricted to activation pro-
voked by self-antigens. It is noteworthy that LPS, acting as a
Toll-like receptor-4 (TLR-4) ligand on antigen-presenting
cells, has been reported to expand precommitted Th17 cells
rather than causing Th17 differentiation [49].
Both TG and TPO induced equivalent numbers of Th10
cells in cultures from healthy donors and HT patients. Con-
cordantly, a study by Glick et al., who grouped HT and GD
together, found equal numbers of CD25hiFoxP3+ Tregs among
AITD patients and healthy donors [28]. Congruent findings
were reported by Pan et al. when investigating subjects with
GD [29]. Our subjects exhibited a skewed balance between
Th17 and Th10 cells, rather than a reduction in antigen-
specific Th10 cells.
The skewing of Th cells from HT patients towards differ-
entiation into Th17 cells rather than Th10 cells may rely
upon an increased propensity to produce Th17-promoting
cytokines during antigen presentation, or upon intrinsic Th
cell factors. Among the cytokines that have been implicated
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Fig. 5. Cytokine production induced by thyroid antigens. Peripheral
blood mononuclear cells (PBMCs) were isolated and stimulated with
thyroglobulin (TG), thyroid peroxidase (TPO), Escherichia coli
lipopolysaccharide or were unstimulated. Concentrations of (a)
transforming growth factor (TGF)-β1, (b) interleukin (IL)-6, (c) IL-1β
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B. Kristensen et al.
8 © 2014 British Society for Immunology, Clinical and Experimental Immunology
Self-antigen induced Th17 and Th10 cells in autoimmune thyroid disease
VC 2014 British Society for Immunology, Clinical and Experimental Immunology, 180: 58–69 65
in Th17 cell differentiation [11,33–36], we quantified TGF-
β1, IL-6 and IL-1β in culture supernatants. Notably, higher
concentrations of TGF-β1 were found in cultures derived
from donors with HT than in those from healthy donors,
irrespective of antigenic stimulus. Also, higher constitutive
levels of IL-6 were found in conditioned medium from
unstimulated HT-derived cultures than in those from
healthy donors. TGF-β and IL-6 have been highlighted as
the differentiation factors for Th17 cells [11,34,35] which
may account, at least in part, for the skewing of HT-derived
Th cells towards Th17-cell differentiation.
As an intrinsic determinant, we looked for abnormalities
in the expression of FoxP3 and the splice variant FoxP3Δ2
in patient-derived cells. FoxP3Δ2 lacks exon 2, the encoded
protein of which plays a critical role in maintenance of
immune homeostasis. Mutations within this exon are asso-
ciated with immune-mediated, polyendocrinopathy, enter-
opathy, X-linked (IPEX) syndrome in humans [50,51]. It is
not known whether full-length FoxP3 and FoxP3Δ2 are
co-expressed or expressed in different cells. We found that,
irrespective of whether or not PBMCs were stimulated with
antigen, 59–67% and 65–73% of the FoxP3 transcripts
expressed by cells from HT or GD patients, respectively,
encoded the FoxP3Δ2 isoform, compared to approximately
30% in healthy individuals. The full-length FoxP3 is known
to suppress the transcription factors retinoic acid-related
orphan receptor (ROR)γt, RORα, nuclear factor of activated
T cells (NFAT) and nuclear factor-kappa B (NF-κB) signal-
ling, while FoxP3Δ2 is incapable of these trophic effects
[47,52–55]. Because RORγt is the essential transcription
factor for Th17 cells, and RORα is expressed highly in TGF-
β/IL-6-induced Th17 cells, the relative over-expression of
FoxP3Δ2 of AITD patients may compromise inhibition of
Th17 differentiation.
Some of the patients had received anti-thyroid drugs
prior to participation in this study. Anti-thyroid drugs may
inhibit lymphocyte function [56,57], in part as a conse-
quence of NF-κB inhibition [58]. It is also possible that the
thyroid status of a patient affects the immune responses
[59]. The low power of this study did not allow adjustment
for relevant covariates including the effect of medication or
thyroid hormones on the observed cytokine responses.
Thus, an influence of these parameters cannot be excluded.
Moreover, in view of the small sample sizes, the findings
reported here should be interpreted cautiously and regarded
as hypothesis-generating.
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In conclusion, our findings demonstrate for the first time
an increased frequency of thyroid antigen-specific Th17
cells in patients with HT in the naive Th cell compartment,
while the abundance of Th10 cells appears to remain unal-
tered. We propose that the tendency of naive Th cells from
HT patients and, to a lesser extent, GD patients to differen-
tiate into Th17 cells could result from an increased expres-
sion of FoxP3Δ2 and diminished inhibition of RORγt.
Furthermore, elevated constitutive TGF-β1 and IL-6 pro-
duction in these patients could contribute to a skew towards
the Th17 phenotype. Studies on larger cohorts of subjects
will be necessary before these possibilities are reported con-
clusively.
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